ELI LILLY & Co (LLY) stock
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 19/3025% above fair value
$1415.55−16.12 (-1.13%)
Close on Nov 17, 2026Market cap $1.33TP/E 45.9Yield 0.44%
Eli Lilly total assets
Total assets on the balance sheet at the end of each period.
Eli Lilly's total assets was $148.07B at Sep 30, 2026. For fiscal 2025 it was $112.48B, up 42.9% from the year before. Over ten years it grew 12.2% a year on average. The highest annual figure on record is $112.48B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $112.48B | +42.9% |
| FY2024 | Dec 31, 2024 | $78.72B | +23.0% |
| FY2023 | Dec 31, 2023 | $64.01B | +29.3% |
| FY2022 | Dec 31, 2022 | $49.49B | +1.4% |
| FY2021 | Dec 31, 2021 | $48.81B | +4.7% |
| FY2020 | Dec 31, 2020 | $46.63B | +18.7% |
| FY2019 | Dec 31, 2019 | $39.29B | -10.5% |
| FY2018 | Dec 31, 2018 | $43.91B | -2.4% |
| FY2017 | Dec 31, 2017 | $44.98B | +15.9% |
| FY2016 | Dec 31, 2016 | $38.81B | +9.1% |
| FY2015 | Dec 31, 2015 | $35.57B | -2.0% |
| FY2014 | Dec 31, 2014 | $36.31B | +3.0% |
| FY2013 | Dec 31, 2013 | $35.25B | +2.5% |
| FY2012 | Dec 31, 2012 | $34.40B | +2.2% |
| FY2011 | Dec 31, 2011 | $33.66B | +8.6% |
| FY2010 | Dec 31, 2010 | $31.00B | +12.9% |
| FY2009 | Dec 31, 2009 | $27.46B | -6.0% |
| FY2008 | Dec 31, 2008 | $29.21B | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $148.07B | +28.8% |
| Q2 FY2026 | Jun 30, 2026 | $142.28B | +41.0% |
| Q1 FY2026 | Mar 31, 2026 | $116.58B | +30.4% |
| Q4 FY2025 | Dec 31, 2025 | $112.48B | +42.9% |
| Q3 FY2025 | Sep 30, 2025 | $114.94B | +52.0% |
| Q2 FY2025 | Jun 30, 2025 | $100.92B | +40.4% |
| Q1 FY2025 | Mar 31, 2025 | $89.39B | +39.8% |
| Q4 FY2024 | Dec 31, 2024 | $78.72B | +23.0% |
| Q3 FY2024 | Sep 30, 2024 | $75.61B | +30.5% |
| Q2 FY2024 | Jun 30, 2024 | $71.87B | +31.1% |
| Q1 FY2024 | Mar 31, 2024 | $63.94B | +20.3% |
| Q4 FY2023 | Dec 31, 2023 | $64.01B | +29.3% |
| Q3 FY2023 | Sep 30, 2023 | $57.92B | +22.0% |
| Q2 FY2023 | Jun 30, 2023 | $54.81B | +16.5% |
| Q1 FY2023 | Mar 31, 2023 | $53.16B | +13.3% |
| Q4 FY2022 | Dec 31, 2022 | $49.49B | +1.4% |
| Q3 FY2022 | Sep 30, 2022 | $47.46B | -1.5% |
| Q2 FY2022 | Jun 30, 2022 | $47.06B | -1.6% |
| Q1 FY2022 | Mar 31, 2022 | $46.92B | +0.2% |
| Q4 FY2021 | Dec 31, 2021 | $48.81B | +4.7% |
| Q3 FY2021 | Sep 30, 2021 | $48.19B | +9.7% |
| Q2 FY2021 | Jun 30, 2021 | $47.81B | +13.9% |
| Q1 FY2021 | Mar 31, 2021 | $46.84B | +14.0% |
| Q4 FY2020 | Dec 31, 2020 | $46.63B | +18.7% |
| Q3 FY2020 | Sep 30, 2020 | $43.95B | +16.0% |
| Q2 FY2020 | Jun 30, 2020 | $41.97B | +8.5% |
| Q1 FY2020 | Mar 31, 2020 | $41.10B | +8.1% |
| Q4 FY2019 | Dec 31, 2019 | $39.29B | -10.5% |
| Q3 FY2019 | Sep 30, 2019 | $37.89B | -15.1% |
| Q2 FY2019 | Jun 30, 2019 | $38.67B | -8.7% |
| Q1 FY2019 | Mar 31, 2019 | $38.01B | -14.3% |
| Q4 FY2018 | Dec 31, 2018 | $43.91B | -2.4% |
| Q3 FY2018 | Sep 30, 2018 | $44.63B | +3.8% |
| Q2 FY2018 | Jun 30, 2018 | $42.36B | +3.5% |
| Q1 FY2018 | Mar 31, 2018 | $44.36B | +17.9% |
| Q4 FY2017 | Dec 31, 2017 | $44.98B | +15.9% |
| Q3 FY2017 | Sep 30, 2017 | $43.01B | – |
| Q2 FY2017 | Jun 30, 2017 | $40.95B | – |
| Q1 FY2017 | Mar 31, 2017 | $37.62B | – |
| Q4 FY2016 | Dec 31, 2016 | $38.81B | – |
See a number that looks wrong?